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Crowdfunding in medical research is becoming more popular due to the shrinking and 
increasingly competitive government funding. In order to inform researchers applying for this 
complementary source of research funding, we investigate the determinants of successful 
crowdfunding campaigns in medical research. We find that establishing and maintaining 
professional contacts through social media is of major importance for successful crowdfunding 
campaigns; an additional tweet or retweet significantly increases the success of crowdfunding 
campaigns. In contrast to the stated preferences of prospective donors, we document that 
crowdfunding campaigns might achieve their fundraising goal regardless of the disease 
characteristics. Scientists thus may ask funding for any kind of project, including therapies for 
rare diseases and diseases with lower mortality rate. 
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Healthcare systems play an important role in meeting the health needs of populations; they are 
crucial to the well-being of individuals and families. Healthcare systems have contributed 
tremendously to the well-being of nations and to the development of social welfare. Rapid 
developments in medical research have opened new possibilities in the treatment of human 
disorders. Over decades, medical innovations resulted in higher life expectancy for citizens and 
generated enormous economic value for the nations (Murphy & Topel, 2006). As a result, 
governments in developed countries are ready to invest heavily in medical research. For 
example, the USA alone spent $3.5tn on healthcare in 2017, out of which $34.2bn were spent 
on medical research by the government supported National Institutes of Health (NIH), the 
largest source of funding for medical research in the world (CMS, 2018; NIH, 2018a). 
Despite the crucial role medical innovation plays in the life of individuals and in the well-being 
of societies, since 2003 available NIH funds have been constantly decreasing in real terms with 
a 5% budget cut in 2013 (Kuehn, 2014). The lower amount of inflation-adjusted funds has been 
coupled with a fierce competition for funding. As a result, the percentage of successfully-
funded medical research projects by NIH decreased from around 33% in 1997 to around 20% 
in 2016 (NIH, 2018b). It is reasonable to assume that the difference in the quality of medical 
research projects that got funding and those which were next best projects but were not funded, 
is marginal. 
The high competition for government funds and the limited funding from the private sector 
prompted researchers to look for alternative financing options. One such option is 
crowdfunding which has gained popularity in various fields, such as technology and art, and 
enabled campaign initiators to efficiently raise funds from a large number of contributors. 
Crowdfunding in medical research is becoming more and more widespread among scientists 
partly due to the general growth of the crowdfunding market and partly due to decreasing 
funding from government institutions. In medical research, crowdfunding campaigns are 
usually donation-based; some campaigns nevertheless offer rewards to donors, such as lab T-
shirts, signed copies of research papers, meetings with scientists (Hughes, 2012). 
The motives for crowdfunding in medical research are diverse. Researchers may turn to 
crowdfunding as a result of unsuccessful grant application for government funding, for 
obtaining some additional funding for an ongoing research, for funding an early phase research 
whose preliminary results serve as a precondition for grant applications or to raise the 
awareness of the general public about an important healthcare issue.  
Considering the positive effect of medical research and innovations on individuals and the 
society as a whole, more widespread crowdfunding by medical researchers might significantly 
improve welfare and benefit the economy on the long term. In this study, we investigate the 
determinants of successful crowdfunding campaigns in medical research, with success being 
measured by the success rate, the ratio of actual funding raised to the fundraising target. The 
determinants identified in this research might serve as guidance for designing and 
implementing successful crowdfunding campaigns in medical research. In particular, we assess 
the impact of four groups of determinants on the success of medical research crowdfunding 
campaigns. First, we look at the characteristics of the disease targeted by the crowdfunding 
campaign. It is reasonable to assume that the crowd is inclined to fund more frequent diseases, 
diseases which are deadlier, diseases which have severe impact on the quality of life of the 
patients, and diseases where the need for the new treatment is high. Second, we investigate the 
peculiarities of the medical research and the potential medical innovation. We hypothesize that 
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highly innovative research approaches and proposals resulting in more effective treatment are 
prioritized by contributors. Third, we assess the impact of organizational details on the success 
rate to see whether donors consider factors such as the type of organization, the qualification 
of the researchers and the availability of additional funding. Finally, we investigate the 
influence of factors describing the design of the crowdfunding campaigns and how researchers 
communicate with the crowd. Previous literature on crowdfunding in other domains 
unambiguously delineate the importance of building a network and communicating efficiently 
with potential donors (Mollick, 2014; Byrnes et al., 2014; Perlstein, 2013; Petitjean, 2018; 
Vachelard et al., 2016). 
This research sheds light on the most important factors influencing the success of crowdfunding 
campaigns in medical research. To the best of our knowledge, this is the first time in the 
literature when factors affecting the success of crowdfunding campaigns in medical research 
are identified in a systematic way. Previous literature on crowdfunding either investigated 
success factors of campaigns in fields other than medical research such as art, design, fashion, 
film, music, publishing and technology (Mollick, 2014; Petitjean, 2018); assessed specific 
aspects of medical crowdfunding campaigns, such as the importance of building an audience 
(Byrnes et al. 2014); or described cases of successful crowdfunding campaigns in medical 
research without systematically assessing the factors (Fumagalli & Gouw, 2015; Dahlhausen 
et al. 2016; Dragojlovic & Lynd, 2014; Perlstein 2013). No studies have yet assessed the impact 
of disease characteristics and the peculiarities of the research setting. 
At the same time, this study allows to compare the stated preferences of prospective donors as 
documented by Dragojlovic and Lynd (2016) with the revealed preferences of campaign 
funders as identified in this research. Dragojlovic and Lynd (2016) conducted an online survey 
of potential donors in North America to determine the characteristics of drug development 
research projects that are most likely to appeal to donors. To enable comparison of stated 
preferences with actual donation purposes, we incorporate 11 out of the 14 attributes identified 
by Dragojlovic and Lynd (2016). The attribute-list of Dragojlovic and Lynd (2016) is 
complemented with a number of additional variables found to influence the success of 
crowdfunding campaigns in various settings other than medical research. 
Dragojlovic and Lynd (2016) report that potential donors are comparatively more inclined to 
support campaigns that aim to treat common diseases, diseases with early age of onset, projects 
where the proposed treatment most likely will cure the disease and patients will not have the 
symptoms anymore. Moreover, potential donors are comparatively also more likely to support 
non-profit organizations, projects where the university of the lead researcher had an excellent 
reputation, and where other funding was available. Stated preferences, however, might deviate 
from revealed preferences. Research in other domains shows that preferences estimated from 
survey experiments do not consistently overlap with the choices made in the real world. For 
example, the inconsistency between survey-based choices (stated preference) and actual 
choices (revealed preference) have been shown when consumers were selecting alternative-
fuel vehicles (Brownstone, Bunch & Train 2000); picking organic or cloned milk (Brooks & 
Lusk, 2010); or young parents had to decide whether to vaccinate their new born child 
(Lambooij et al. 2015). Beshears, Choi, Laibson and Madrian (2008) enumerate five factors 
that increase the likelihood of inconsistency between the agents’ interests and observed actions: 
passive choice, limited personal experience, complexity, third-party marketing, and 
intertemporal choice. Stated behavioural intentions might be inconsistent predictors of future 
decisions in medical research crowdfunding as well. By looking at the factors listed by 
Beshears et al. (2018), stated and revealed donation behaviour might deviate from each other 
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due to limited personal experience, complexity, and third-party marketing. Due to limited 
personal experience with the complex medical peer review process, donors might prefer 
supporting the scientists they either know personally or professionally or from the media. 
Scientists and universities with high reputation might also be preferred by donors; their 
reputation serve as an effective marketing tool. Finally, donors might have acquaintances who 
suffer from the disease and they are eager to provide financial support for campaigns focusing 
on the disease of their loved ones. 
To preview our results, we find that establishing and maintaining professional contacts through 
social media is of major importance for successful crowdfunding campaigns; an additional 
tweet or retweet increases the success rate of crowdfunding campaign by one percentage point. 
Our results suggest that researchers should carefully consider the platform on which they plan 
to launch their crowdfunding campaign; platforms with large numbers of users might pay off, 
even if they are profit-oriented and charge a fee. The fundraising goal should be realistic and 
attainable; we find empirical evidence that the higher the fundraising goal, the lower the 
probability of succeeding. Moreover, we report that crowdfunding campaigns might achieve 
their fundraising goal regardless of the disease characteristics. Scientists thus may ask funding 
for any kind of project, including therapies for rare diseases, diseases with early age of onset, 
and diseases with low mortality rate. 
At the same time, when comparing the actual donation behaviour documented in this research 
with the stated preferences of prospective donors as reported by Dragojlovic and Lynd (2016), 
we find empirical evidence of inconsistency between stated and revealed preferences in 
crowdfunding. In this research, none of the attributes found influential by Dragojlovic and 
Lynd (2016) were useful in predicting the success rate of crowdfunding campaigns. Stated 
charitable attitudes and behaviour alone thus cannot be used to forecast actual donation 
behaviour in crowdfunding medical research. 
 
2. Materials and methods 
2.1 Crowdfunding campaigns 
Data about crowdfunding campaigns in medical research is obtained from www.consano.org 
and www.experiment.com, two crowdfunding platforms being specialized in funding scientific 
research. These two platforms were chosen after assessing the content and suitability of the 
crowdfunding platforms listed by Cadogan (2014) and Dragojlovic and Lynd (2014). The main 
criteria for inclusion were as follows: 
1. The platform is among the largest crowdfunding platforms in the US focusing on 
scientific (medical) research. The geographical constraint was imposed with the aim 
of comparing the actual funding behaviour with the stated preferences of potential 
donors from North America (Dragojlovic and Lynd, 2016). 
2. The platform covers a variety of diseases instead of a single one, such as cancer or 
diabetes. 
3. Information about past projects is available. 
4. The platform presents sufficient information about the medical research and the 
research team. 
The platform Consano is a non-profit crowdfunding platform devoted to medical research; the 
researchers can keep any funds raised, even if the target is not met (Consano, 2017a). In total, 
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64 projects were initiated on this platform, the amount raised exceeded $1m (Consano, 2017b). 
The platform Experiment is profit-oriented, it charges 8% platform fee (Experiment, 2017a). 
This latter platform follows the ‘all-or-nothing’ model; only fully funded projects get the 
donations. By the end of 2017, 743 projects were funded, and $7.6m were pledged by 40,206 
backers (Experiment, 2017b). Neither Consano nor Experiment provide tangible rewards; 
however, project results are shared either with the general public or with the backers only. 
Medical research crowdfunding campaigns from these two platforms were included in the 
sample if they were closed as of 12 February 2018, the final date of data collection. The final 
sample includes 109 projects, 81 projects from Experiment and 28 from Consano. This sample 
size is comparable to those used in several prior studies (e.g., Byrnes et al., 2014; Dragojlovic 
& Lynd, 2014; Petitjean, 2018).  
 
2.2 Factors influencing the success of crowdfunding campaigns 
The success rate of campaigns, defined as the percentage of the target sum raised, is used as a 
dependent variable. Such a dependent variable allows comparison of crowdfunding campaigns 
with different funding goals. 
Independent variables cover the attributes defined by Dragojlovic and Lynd (2016); those 
attributes were selected after carefully reviewing the crowdfunding literature and consulting 
university fundraising experts. From the 14 attributes defined by Dragojlovic and Lynd (2016), 
two attributes were excluded from this research due to data unavailability: 1) the source of 
fundraising appeal showing the relationship of the backers with the organization asking for 
donations, and 2) matching donations showing whether each dollar donated to the campaign is 
matched with any other contribution. In addition, the subjective attribute of university 
reputation was replaced by the number of research team members with PhD degrees serving as 
a proxy for the prestige and credibility of the crowdfunding team. 
Independent variables are divided into four groups: disease characteristics (Table 1, Panel A), 
peculiarities of the medical research (Table 1, Panel B), organizational details (Table 1, Panel 
C) and characteristics of communication and design (Table 1, Panel D). The attribute-list of 
Dragojlovic and Lynd (2016) was complemented with some additional variables (Table 1, 
Panels A-C). To deal with the diverse dataset, among the disease characteristics we 
differentiate between campaigns related to humans and animals (Table 1, Panel A), whereas 
among the medical research characteristics we differentiate between campaigns researching a 
particular topic and developing a cure for a disease (Table 1, Panel B).  
Furthermore, we add several variables describing the design of the crowdfunding campaigns 
and how researchers communicate with the crowd (Table 1, Panel D): the number of tweets, 
retweets and comments; number of updates; availability of intermediate research findings; 
availability of photos and videos; the length of the campaign description; and the crowdfunding 
platform on which the campaign is running. The inclusion of these predictors, not covered by 
the survey of Dragojlovic and Lynd (2016), is supported by recent empirical evidence. Previous 
literature on crowdfunding unambiguously suggests the importance of building a network (Hui, 
Gerber & Gergle 2014; Mollick, 2014; Byrnes et al., 2014; Perlstein, 2013; Petitjean, 2018; 
Vachelard et al., 2016). Having a large online social network and sharing information about 
crowdfunding campaigns on these networks, such as Facebook and Twitter, increases the 
probability of reaching potential donors and thus the success of crowdfunding campaigns. In 
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the literature, the size of the social network is commonly proxied with the number of Facebook 
friends and/or with the number of Twitter followers. Both the number of Facebook friends 
(Mollick, 2014; Byrnes et al., 2014) and the number of tweets and retweets (Byrnes et al., 2014) 
are found to be positively associated with the success of crowdfunding campaigns; the latter 
variable is included in our model. 
Table 1: Factors influencing the success of crowdfunding campaigns 
 
Variable Name  Explanation 
Panel A: Disease characteristics  
Human/Animal human Binary variable; 1 if the campaign is about humans, 0 if it is related to 
animals. Age of onset* – age 5 
age 5 – age 40 
age 40 – age 50 
age 50 – age 70 
Age t which most patients acquire symptoms of a disease. Binary 
variable; 1 if the symptoms are typically acquired by age of 5, 40, 50 or 




freq Disease frequency per 100,000 people. 
Impact on quality 
of life* 
quality Binary variable; 1 if the impact of the disease on the quality of life of a 
patient is severe, 0 if moderate. The impact is severe if the disease causes 
severe pain and discomfort and prevent patients from living at home due 
to their disabilities. The impact is moderate if the disease causes 
moderate pain and discomfort, and patients face difficulties in conducting 
their daily activities. 





Binary variable; 1 if the need for new treatments is low, medium, or high, 
respectively, 0 otherwise.The need is high if there are no currently 
approved treatments for the disease; medium if a treatment is available, 
but only increases the length and/or quality of life by a small amount. The 
need is low if a treatment which significantly increases the length and/or 
quality of life of patients is available. The reference category is the 
medium need for new treatments. 
Mortality rate* mortality Proportion of patients with this disease who die within 10 years after 
receiving the diagnosis. 
Panel B: Medical research characteristics  
Cure/Research cure Binary variable; 1 if the campaign aims at developing a cure for a 
disease, 0 if it aims at researching the phenomenon. 
Innovation level* innovation Binary variable; 1 if the innovation level of the proposed medical 
research is high, 0 if it is low. The innovation level is considered as high 
if the researchers come up with an innovative approach that has never 
been used previously to cure the disease or was used in a very different 
context. The innovation level is considered as low if researchers test 





effectiveness Binary variable; 1 if the proposed treatment will most likely cure the 
disease, 0 if patients will significantly benefit from the treatment, but the 






Binary variable; 1 if a development stage is early, mid or late, 
respectively, 0 otherwise. In case of developing a cure for a disease, the 
development stage is early if the research team tests the effectiveness and 
toxicity of a large number of possible drugs in the lab using human cells; 
mid if they perform tests on mice; late if the drug is tested on humans. In 
case of researching a phenomenon, the development stage is early if 
there is only an general idea about experiment to be conducted; mid if the 
idea has already been tested and first results are available; late if several 
experiments has been conducted, and additional funding is needed to 
answer questions which were developed during the experiments. The 
reference category is the early development stage. 
Fundraising goal* funding goal The fundraising goal of the campaign, in US dollars. 
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Panel C: Organizational characteristics 
Type of 
organization* 
org Binary variable; 1 if the organization is for-profit, 0 if it is non-profit. 
Number of people 
with PhD 
phd Number of people in the research team with a PhD degree. 
Availability of 
other funding* 
additional fund Binary variable; 1 if additional funding is available, 0  otherwise. 
Panel D: Communication and design 
Tweets & 
retweets 
twit Number of tweets sharing the campaign from open accounts plus the 
number of retweets, excluding repeated tweets from the same account. 
Comments comments Number of comments on the project page, excluding comments posted 
after the closing date. 
Photo photo Binary variable; 1 if there are photos on the campaign page, 0 otherwise. 
Video video Binary variable; 1 if there is a video on the campaign page, 0 otherwise. 




interim results Binary variable; 1, if intermediate results are available, 0 otherwise. 
Length length Length of the campaign description measured by the number of words. 
Platform platform Binary variable; 1 if a project was posted on experiment.com, 0 if it is 
from consano.org. 
* Variable adopted from Dragojlovic and Lynd (2016) 
 
Having a large audience is a necessary but not sufficient condition for success researchers 
should also communicate efficiently with potential donors, both inside and outside their social 
network. This efficient communication may take several forms. Empirical evidence shows the 
importance of comments left by backers on the campaign’s website (Berliner & Kenworthy, 
2017; Mollick, 2014; Petitjean, 2018); the necessity of utilizing multimedia tools and adding 
photos and videos to the campaign (Berliner & Kenworthy, 2017; Mollick, 2014; Makris, 2015; 
Petitjean, 2018; Vachelard et al., 2016); and posting regular updates and disclosing 
intermediate research findings (Mollick, 2014; Xu et al., 2014). Finally, the length of the 
campaign description as an independent variable is motivated by the research of Moy, Chan 
and Torgler (2018) who find that excessive amount of information negatively affects the fund 
raised. All these aspects of communication are captured by variables defined in Table 1, Panel 
D. 
Data was collected manually. Variables were obtained from the descriptions of the 
crowdfunding campaigns with three exceptions: age of onset, 10-year mortality rate, and 
disease frequency. Such information was typically not included in the campaign description; 
these variables were determined from various health databases and journal articles. The final 
dataset, available upon request from the authors, includes the methodology of data collection, 
the source of additional information, and the value for each variable. In case of missing data, 
the mean-substitution approach was employed (Schafer & Graham, 2002).  
 
2.3 Regression analysis 
Ordinary Least Squares (OLS) regressions are employed to identify the success factors of 
medical crowdfunding campaigns. These revealed preferences are then compared with the 
stated preferences as determined by Dragojlovic and Lynd (2016). In this research, OLS 
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regressions are preferred over binary response models such as the logit or the probit models; 
we exploit the information embedded in the extent of underfunding vs overfunding. The 
success rate shows a large variability, it ranges from 3% to 489% in the datasethad we 
focused on the fact whether the funding target was reached, information would have been lost. 
The regression model is specified as follows: 
𝑆𝑢𝑐𝑐𝑒𝑠𝑠 𝑟𝑎𝑡𝑒𝑖 = 𝛽0 + ∑ 𝛽𝑗
𝑛
𝑗=1 𝑋𝑖𝑗,        (1) 
where 𝛽0 is the intercept and 𝑋𝑖𝑗 corresponds to independent variable j for campaign i. OLS 
regressions are tested for multicollinearity, variance inflation factor (VIF) test is employed. 
VIF values range from 1.27 to 3.80 with an average value of 2.01. VIF values lower than 5 
indicate that multicollinearity is not a problem in these regressions (Montgomery, Peck, & 
Vining, 2012). Outliers are detected by plotting a scatterplot matrix for four non-binary 
variables (disease frequency, fundraising goal, tweets&retweets, and comments). We apply a 
95% winsorization for outliers; extreme values outside the confidence interval of 95% (2.5% 
from both sides of the distribution) are replaced by the upper and lower 2.5% percentile values.  
In the first model, independent variables enter the regression as shown in Table 1. In the second 
model, in line with the stated preference survey of Dragojlovic and Lynd (2016) categorical 




3. Results and discussion 
3.1 Descriptive statistics 
Descriptive statistics of the independent variables are shown in Table 2. For binary variables, 
the mean value provides information about the proportion of observations having a value of 1. 
Descriptive statistics of the categorical variables used in the second model are shown in Table 
A1, in the Appendix. 
 
Table 2: Descriptive statistics (N=109) 
 
Variable Mean Std. Dev. Min Max 
Panel A: Disease characteristics         
human/animal (1 human; 0 animal) 0.89 0.31 0.00 1 
age 5 0.03 0.16 0.00 1 
age 5  age 40 0.28 0.45 0.00 1 
age 40  age 50 0.05 0.21 0.00 1 
age 50 age 70 0.64 0.48 0.00 1 
freq (per 100,000 people) 568.46  1,372.21  0.04 13,000  
freq winsorized (per 100,000 people) 453.79  568.36  0.73 3,000  
quality (1 severe; 0 moderate) 0.72 0.45 0.00 1 
treat_low 0.26 0.44 0.00 1 
treat_medium 0.56 0.50 0.00 1 
treat_high 0.18 0.39 0.00 1 





Panel B: Medical research characteristics 
cure (1 cure; 0 research) 0.35 0.48 0.00 1 
innovation (1 high; 0 low) 0.72 0.45 0.00 1 
effectiveness (1 cure; 0 benefit) 0.94 0.25 0.00 1 
devel_st_early 0.78 0.42 0.00 1 
devel_st_mid 0.21 0.41 0.00 1 
devel_st_late 0.01 0.10 0.00 1 
funding goal 19,179.34  96,002.68  350.00 1,000,000  
funding goal winsorized 10,470.63  15,147.36  800.00 75,000  
Panel C: Organizational characteristics       
org (1 for-profit; 0 non-profit) 0.06 0.25 0.00 1 
phd (number of researchers) 0.72 1.02 0.00 5 
additional fund (1 yes; 0 no) 0.28 0.45 0.00 1 
Panel D: Communication and design         
twit 28.27 206.64 0.00 2,155  
twit winsorized 9.38 22.30 0.00 115  
comments 16.84 36.81 0.00 303  
comments winsorized 15.26 26.67 0.00 139  
photo 0.77 0.42 0.00 1 
video 0.64 0.48 0.00 1 
updates 3.78 5.65 0.00 28 
interim results 0.28 0.45 0.00 1 
length 900.92 323.20 427.00 1,706  
platform (1 Experiment; 0 Consano) 0.74 0.44 0.00 1 
For the four variables with outliers, figures in italics show the descriptive statistics after winsorization. 
 
3.2 Regression analysis 
OLS regression results of the first model are shown in Table 3. Similar conclusions can be 
drawn from the second model (Table A2, Appendix). 
Communication plays an important role in launching a successful crowdfunding campaign. 
The coefficient of the tweets&retweets (twit winsorized) variable is positive and significant; 
an additional tweet or retweet increases the success rate of a campaign by 1.79. The positive 
and significant effect of the number of tweets on the success of crowdfunding campaigns is in 
line with previous findings. Perlstein (2013) estimate that in their pharmacological 
Crowd4Discovery crowdfunding campaign 60% of the donors were part of his social networks 
in Facebook and Twitter. At the same time, Byrnes et al. (2014) swon that engagement of a 
large audience is of major importance to successful crowdfunding in science. In order to 
engage, scientists first have to build an audience for their research through the press and online 
social media such as Facebook and Twitter. Once the audience is built and the crowdfunding 
campaign is on, scientist should maintain the public presence through tweets, e-mails or press 
releases. As a result of these tweets, e-mails and press appearances, people will view the project 
page and donate. Vachelard et al. (2016) also argue that the success of the crowdfunding 
campaign heavily depends on the social network of the fundraisers. They suggest the 





Table 3: OLS regression results 
 
Variables coefficients p-value 95% CI 
Disease characteristics       
human/animal 4.89 0.91 [-23.26-26.22] 
age5  age 40 0.90 0.81 [-59.32-75.89] 
age 40  age 50 18.58 0.33 [-100.81-34.14] 
age 50  age 70 -28.378* 0.93 [-64.65-59.4] 
freq winsorized 0.01 0.50 [-0.01-0.02] 
quality 24.60 0.13 [-8.2-61.33] 
treat_low 24.99 0.08 [-2.78-51.59] 
treat_high 20.35 0.17 [-11.43-64.98] 
mortality (10 years) 0.16 0.44 [-0.25-0.58] 
Medical research 
characteristics       
cure 3.13 0.75 [-16.17-22.42] 
innovation -20.12* 0.03 [-38.45--1.8] 
effectiveness 7.58 0.55 [-17.45-32.61] 
devel_st_mid 13.12 0.35 [-14.62-40.86] 
devel_st_late -17.62 0.30 [-50.87-15.62] 
funding goal winsorized -0.0008* 0.04 [-0.0016-0.0000] 
Organizational characteristics       
org -26.79 0.33 [-81.18-27.6] 
phd 5.56 0.33 [-5.77-16.89] 
additional fund 2.37 0.83 [-19.23-23.97] 
Communication and design       
length -0.01 0.44 [-0.03-0.01] 
comments winsorized -0.56 0.07 [-1.17-0.04] 
twit winsorized 1.79*** 0.00 [0.84-2.75] 
photo -14.06 0.18 [-34.69-6.57] 
video 7.31 0.51 [-14.51-29.13] 
updates 1.43 0.19 [-0.71-3.57] 
results -3.90 0.72 [-25.02-17.23] 
platform 38.86* 0.01 [9.46-68.27] 
* p<0.05. ** p<0.01, *** p<0.001 
 
Coefficients that are significant at least at the 5% level are highlighted in bold. The R-squared of the model is 
0.5873, while the adjusted R-squared is 0.4565. 
 
Our results suggest that fundraisers should select the crowdfunding platform carefully. If a 
campaign is launched on Experiment, the success rate of the campaign is by 38.86 and 48.80 
percentage points higher as compared to launching the campaign on Consano. On the one hand, 
Experiment is a larger platform than Consano with 20 project categories, a few of them being 
related to medical research. Due to the larger pool of project categories and projects, higher 
number of potential donors visit the website. Potential donors might spill over from those other 
categories into the category of medical research. On the other hand, total funding per successful 
project, on average, is smaller on Experiment than on Consano (USD 10,229 vs USD 15,625), 
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which makes it easier to raise the target sum (Consano, 2017b, Experiment 2017b). In case of 
Experiment, the fundraisers do not get the pledged funds until the target is met; a rule which 
motivates fundraisers to set realistic financial goals. 
The variable of fundraising goal is significant at 5% with a negative beta coefficient; the 
success rate of the campaign is marginally smaller, if the target sum is higher. This finding is 
in line with Mollick (2014) and Petitjean (2018), who arrived at the same conclusion by 
analysing 48,526 US-based campaigns listed on Kickstarter and 160 campaigns launched on 
the French KissKissBankBank platform, respectively. 
The variable of innovation is significant at 5% with a negative beta coefficient; the more 
innovative the project is, the lower the probability of raising the target sum. Donors are risk 
averse, they disprefer projects where researchers employ an innovative approach that has never 
been used previously to cure the disease or was used in a very different context.  
When comparing the actual donation behaviour documented in this research with the stated 
preferences of potential donors as reported by Dragojlovic and Lynd (2016), we find empirical 
evidence of inconsistency between stated and revealed preferences in crowdfunding. 
Dragojlovic and Lynd (2016) report that potential donors were comparatively more inclined to 
support campaigns that aim to treat diseases with early age of onset (pediatric diseases and 
diseases where patients acquire the symptoms in young adulthood and early middle age). 
Potential donors also showed strong preference for supporting projects which are more 
frequent. Moreover, potential backers were likely to provide donations for projects where the 
proposed treatment most likely cures the disease and patients do not have to live with the 
symptoms anymore. Potential donors were comparatively also more likely to support non-
profit organizations, projects where the university of the lead researcher had an excellent 
reputation, and where other funding was available. Potential donors also stated to prioritize 
projects, albeit to a lesser extent, where the impact on the quality of life of patients is severe 
and the mortality is high. In this research, none of these attributes were useful in predicting the 
success rate of crowdfunding campaigns. Stated charitable attitudes and behaviour thus cannot 
be used to forecast actual donation behaviour in crowdfunding medical research.  
Several factors might explain why stated and revealed preferences differ and why disease 
characteristics are irrelevant in crowdfunding medical research. First, donors might be part of 
the fundraisers’ personal or professional network and provide financial support to the scientists 
they know without considering the disease characteristics. This argument is supported by the 
estimate of Perlstein (2013), who reported that in their pharmacological campaign he was 
connected to 60% of the donors through social media. Second, donors might have friends or 
relatives who suffer from the disease and they are eager to provide financial support with the 
hope of easing the burden of their loved ones. Third, donors might be biased towards 
crowdfunding campaigns launched by recognized and prestigious universities or influential and 
highly respected scientists. Fourth, donors’ actual funding behaviour may deviate from the 
planned one due to herding bias. If numerous people share information about a crowdfunding 
campaign on social networks, for example via tweets, donors might follow the consensus and 
end up funding that campaign. 
Crowdfunding medical research is becoming more and more popular; it serves as an additional 
tool for financing research initiatives. The revealed preferences documented in this research 
might help scientists to pursue a successful crowdfunding campaign. Our findings highlight 
the importance of establishing and maintaining professional contacts through social media; an 
additional tweet or retweet increases the success rate of crowdfunding campaign by one 
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percentage point. Nardi, Whittaker and Schwarz (2002) list three main tasks for keeping a 
successful professional network: building a network, maintaining the network and activating 
selected contacts. Tweeting is a tool for activating members in the personal and professional 
networks; scientists shall put effort in establishing and keeping up-to-date their networks 
beforehand. 
Our results suggest that researchers should select the platform on which they plan to run their 
crowdfunding campaign carefully. Platforms with wider publicity are to be preferred over 
specialized, smaller platforms; the pool of potential donors is larger and thus the possibility of 
achieving the fundraising target is higher. More popular platforms might pay off, even if they 
are profit-oriented and charge a fee. At the same time, researchers should not set unrealistic 
funding goals as they might discourage donors from providing financial support.  
Researchers may ask funding for any kind of project, including therapies for rare diseases and 
disorders where the first symptoms appear at later age of onset. Our results suggest that 
crowdfunding campaigns might reach their fundraising goal regardless of the disease 
characteristics such as disease frequency and age of onset. This finding matches the concern 
listed by Del Salvio (2017). As argued by the author, in crowdfunding, financial resource 
allocation is based on the judgement of donors not being experts in medical sciences. As a 
result, the public fails to allocate resources efficiently and prioritize research delivering the 
highest total value to the society. Nevertheless, it might be easier to build and engage an 
audience where the disease characteristics overlap with the stated preferences of the potential 
donors. Stated preferences reflect the attributes that donors and generally the wider public care 
about: diseases with high mortality rate, diseases with early age of onset, frequent diseases, and 
diseases causing severe pain and discomfort. Stated preferences are generally in line with the 
principles of resource allocation in healthcare: resources should be allocated where the largest 
total improvement is expected, that is, more people are affected, the quantity of life lived 
significantly increases, and the quality of life substantially improves. The total improvement is 
typically measured by the quality adjusted life year covering both the quality and the quantity 
of life lived; it is a widely used measure to assess the value for money of various interventions 
in healthcare, including funding (Angelis, Kanavos & Montibeller, 2017; Brazier, Deverill & 
Gree, 1999; Wouters, Naci & Samani, 2015). 
This research has several limitations. First, we focused on platforms which cover a variety of 
diseases; the success factors on platforms specialized on a single disease might slightly differ. 
Second, the number of observations is small (109 campaigns), while the number of independent 
variables is high (30 predictors). Austin and Steyerberg (2015), however, argue that linear 
regressions require only two subject per variable for estimating the regression coefficients, 
standard errors, and confidence intervals adequately (i.e., with a relative bias of less than 10%). 
Third, we disregard when the information became available to the potential backers. Although 
the number of comments, tweets and updates evolve over time, in the model the values 
observed at the end of the campaign are included. Fourth, information about disease frequency, 
age of onset and mortality were obtained from scientific journals. Although two researchers 




As government funded research grants for medical research are scant and have become 
increasingly competitive, scientists are prompted to search for alternative financing options. 
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Crowdfunding might be regarded as a feasible option for funding medical research. 
Crowdfunding has the potential to complement but not to replace existing government funding. 
Central funding agencies should keep on fostering fundamental discoveries, innovative 
research approaches and their application as a basis for improving the health and wealth of the 
nations. These funding agencies should continue assuring efficient allocation of resources, and 
prioritize research which delivers the highest total value to the society, considering both the 
quality and the quantity of life lived, summed up across all individuals. As shown in this study, 
crowdfunding in medical research disregards the disease characteristics and the total value 
delivered to the society.  In crowdfunding, scientists with large social networks, either personal 
or professional, are more likely to achieve their fundraising goal. Scientists who managed to 
develop good networking skills and/or their research became widely covered in the media have 
higher chances to succeed. From this respect crowdfunding imposes a negative externality on 
the society; campaigns are not evaluated on their merit they deliver to the society as a whole. 
This negative externality is nevertheless outweighed by the positive externality crowdfunding 
in medical research delivers to the society. Through crowdfunding additional financial 
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Appendix, Table A1: Descriptive statistics of variables in model 2 (N=109) 
 
Variable Mean Std. Dev. Min Max 
Panel A: Disease characteristics         
human/animal (1 human; 0 animal) 0.89 0.31 0.00 1 
age 5 0.03 0.16 0.00 1 
age 5  age 40 0.28 0.45 0.00 1 
age 40  age 50 0.05 0.21 0.00 1 
age 50 age 70 0.64 0.48 0.00 1 
 freq 1 in 15 0.01 0.10 0.00 1 
freq 1 in 15 1 in 50 0.03 0.16 0.00 1 
freq 1 in 50  1 in 1,000 0.62 0.49 0.00 1 
freq 1 in 1,000  1 in 100,000 0.31 0.47 0.00 1 
freq 1 in 100,000  0.03 0.16 0.00 1 
quality (1 severe; 0 moderate) 0.72 0.45 0.00 1 
treat_low 0.26 0.44 0.00 1 
treat_medium 0.56 0.50 0.00 1 
treat_high 0.18 0.39 0.00 1 
mortality 0-5% (10 years) 0.06 0.25 0.00 1 
mortality 5%-40% (10 years) 0.12 0.33 0.00 1 
mortality 40%-80% (10 years) 0.72 0.45 0.00 1 
mortality 80%-100% (10 years) 0.09 0.29 0.00 1 
Panel B: Medical research characteristics       
cure (1 cure; 0 research) 0.35 0.48 0.00 1 
innovation (1 high; 0 low) 0.72 0.45 0.00 1 
effectiveness (1 cure; 0 benefit) 0.94 0.25 0.00 1 
devel_st_early 0.78 0.42 0.00 1 
devel_st_mid 0.21 0.41 0.00 1 
devel_st_late 0.01 0.10 0.00 1 
 goal 40k 0.94 0.23 0.00 1 
goal 40k 300k 0.05 0.21 0.00 1 
goal 300k  goal 1m 0.01 0.10 0.00 1 
Panel C: Organizational characteristics       
org (1 for-profit; 0 non-profit) 0.06 0.25 0.00 1 
phd (number of researchers) 0.72 1.02 0.00 5 
additional fund (1 yes; 0 no) 0.28 0.45 0.00 1 
Panel D: Communication and 
design         
twit 28.27 206.64 0.00   2,155  
twit winsorized 9.38 22.30 0.00 115  
comments 16.84 36.81 0.00 303  
comments winsorized 15.26 26.67 0.00  139  
photo 0.77 0.42 0.00 1 
video 0.64 0.48 0.00 1 
updates 3.78 5.65 0.00 28 
interim results 0.28 0.45 0.00 1 
length 900.92 323.20 427.00 1,706  
platform (1 Experiment; 0 Consano) 0.74 0.44 0.00 1 
 
Variables highlighted in grey denote the categorical variables used in the second model. For the four 
variables with outliers, figures in italics show the descriptive statistics after winsorization. 
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Table A2: OLS regression results of model 2 
 
Variables coefficients p-value 95% CI 
Disease characteristics       
human/animal 1.48 0.72 [-22.27-32.05] 
- age 5 2.63 0.64 [-56.3-91.67] 
age 5 - age 40 10.91 0.42 [-101.19-42.64] 
age 40 - age 50 -30.71 0.98 [-64.71-62.91] 
freq 1 in 15 - 1 in 50 2.21 0.91 [-35.95-40.37] 
freq 1 in 50 - 1 in 1,000 7.82 0.47 [-13.52-29.16] 
freq 1 in 100,000 - -24.65 0.42 [-85.39-36.09] 
quality 26.57 0.17 [-10.3-59.51] 
treat_low 24.41 0.08 [-3.13-53.11] 
treat_high 26.78 0.29 [-17.58-58.28] 
mortality 0-5% (10 years) -22.07 0.33 [-67.01-22.87] 
mortality 5%-40% (10 years) -10.29 0.50 [-40.15-19.57] 
mortality 80%-100% (10 years) 1.14 0.95 [-36.86-39.14] 
Medical research characteristics     
cure 2.42 0.81 [-17.26-22.11] 
innovation -15.94 0.11 [-35.66-3.77] 
effectiveness 12.54 0.39 [-16.14-41.23] 
devel_st_mid 16.80 0.27 [-13.54-47.15] 
devel_st_late -17.86 0.37 [-57.47-21.75] 
goal 40k - 300k -36.18 0.18 [-89.9-17.53] 
Organizational characteristics  
org -25.70 0.31 [-75.9-24.5] 
phd 5.43 0.33 [-5.69-16.56] 
additional fund -0.39 0.97 [-23.55-22.78] 
Communication and design       
length -0.01 0.46 [-0.03-0.01] 
comments winsorized -0.54 0.06 [-1.09-0.02] 
twit winsorized 1.72*** 0.00 [0.77-2.68] 
photo -11.58 0.29 [-33.36-10.2] 
video 4.43 0.67 [-16.17-25.04] 
updates 1.23 0.23 [-0.79-3.25] 
results -6.48 0.55 [-28.08-15.12] 
platform 48.80*** 0.00 [20.91-76.68] 
 
* p<0.05. ** p<0.01, *** p<0.001 
 
Variables highlighted in grey denote the categorical variables used in the second model. Coefficients 
that are significant at least at the 5% level are highlighted in bold. The R-squared of the model is 0.5850, 
while the adjusted R-squared is 0.4254. For categorical variables the table excludes the reference 
category. As a result of winsorization, two categories have zero observations (disease being more 
frequent than 1 in 15; fundraising goal 300k - goal 1m); these categories are not shown in the table. 
